150 related articles for article (PubMed ID: 38602057)
1. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
Samalin L; Boudieu L; Llorca PM
Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
McIntyre RS; Such P; Yildirim M; Madera-McDonough J; Zhang Z; Larsen F; Harlin M
Curr Med Res Opin; 2023 Jul; 39(7):1021-1030. PubMed ID: 37272079
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
Harlin M; Chepke C; Larsen F; Bell Lynum KS; Chumki SR; Fitzgerald H; Such P; Madera-McDonough J; Yildirim M; Panni M; Saklad SR
Neuropsychiatr Dis Treat; 2023; 19():1409-1416. PubMed ID: 37313228
[TBL] [Abstract][Full Text] [Related]
9. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
Citrome L; Such P; Yildirim M; Madera-McDonough J; Beckham C; Zhang Z; Larsen F; Harlin M
J Clin Psychiatry; 2023 Sep; 84(5):. PubMed ID: 37672016
[No Abstract] [Full Text] [Related]
14. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L
Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
[TBL] [Abstract][Full Text] [Related]
16. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
17. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
Kishi T; Citrome L; Sakuma K; Iwata N
Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
[TBL] [Abstract][Full Text] [Related]
18. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
[No Abstract] [Full Text] [Related]
19. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
